Evidence map›Paper›PMID 40576884›Full record

GuidelineHormones (Athens, Greece)2025

Diagnosis and management of hypoparathyroidism: recommendations of the working group of the Bone Section of the Hellenic Endocrine Society.

Evanthia Kassi, Fotini Adamidou, Maria P Yavropoulou, Athanasios D Anastasilakis, Polyzois Makras, Andromachi Vryonidou, Symeon Tournis

Erratum issued Registry-linked trialAbstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07299838 (Real-World Data for Effectiveness and Safety of Palopegteriparatide in Patients With Chronic Hypoparathyroidism in Greece), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07299838 completednot on this map

Real-World Data for Effectiveness and Safety of Palopegteriparatide in Patients With Chronic Hypoparathyroidism in Greece

TypeobservationalSponsorNational and Kapodistrian University of AthensRan2024 to 2025Enrolled90ConditionsHypoparathyroidism
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Evanthia KassiCentre of Expertise in Rare Endocrine Diseases, Endocrinology Unit, 1st Department of Propaedeutic Internal Medicine, C.E.R.E.D-Disorders of Calcium and Phosphate Metabolism (ENDO-ERN accredited), LAIKO General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece.
Fotini AdamidouDepartment of Endocrinology and Diabetes, Hippokratio General Hospital, Thessaloniki, Greece.
Maria P YavropoulouCentre of Expertise in Rare Endocrine Diseases, Endocrinology Unit, 1st Department of Propaedeutic Internal Medicine, C.E.R.E.D-Disorders of Calcium and Phosphate Metabolism (ENDO-ERN accredited), LAIKO General Hospital of Athens, National and Kapodistrian University of Athens, Athens, Greece.
Athanasios D AnastasilakisDepartment of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece.
Polyzois MakrasDepartment of Endocrinology and Diabetes, Department of Medical Research, 251 Hellenic Air Force General Hospital, Athens, Greece.
Andromachi VryonidouDepartment of Endocrinology and Diabetes, Hellenic Red Cross Hospital, Athens, Greece.
Symeon TournisLaboratory for Research of the Musculoskeletal System "Th. Garofalidis", Medical School, National and Kapodistrian University of Athens, KAT Hospital, 10 Athinas Str, Kifissia, Athens, PC: 14561, Greece. stournis@med.uoa.gr.ORCID http://orcid.org/0000-0002-8301-324X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoparathyroidism (HypoPT) is a rare endocrine disorder characterized by hypocalcemia accompanied by low or inappropriately normal parathyroid hormone (PTH) levels. The Bone Section of the Hellenic Endocrine Society reviewed the available evidence and the recent international guidelines and provided updated clinical practice recommendations for the diagnosis and optimal management of patients with HypoPT. Specifically, permanent post-surgical HypoPT should be considered if the disorder persists for more than 12 months after surgery, while in non-surgical cases, appropriate genetic testing should be applied, especially in young patients or those with syndromic features. In addition, the current report provides recommended and suggested laboratory and imaging examinations for the optimal management of patients with HypoPT. Concerning management, the panel recommends conventional therapy with calcium and vitamin D analogs as first-line treatment, while in patients with inadequate disease control, PTH replacement therapy should be considered with close monitoring. Finally, the challenges of the diagnosis and management of HypoPT in pregnancy are also discussed.

Indexed as

EndocrinologyHypoparathyroidismCalciumFemaleHumansParathyroid HormonePregnancyReview Literature as TopicSocieties, MedicalVitamin DCalciumParathyroid HormoneVitamin DConventional treatmentHyperphosphatemiaHypocalcemiaHypoparathyroidismPTH replacement

Identifiers

PMID40576884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.